4th Antibody-Drug Conjugate (ADC) Toxicity Summit

4th Antibody-Drug Conjugate (ADC) Toxicity Summit is organized by Hanson Wade and will be held from Aug 25 - 27, 2026 at Revere Hotel Boston Common, Boston, Massachusetts, United States of America.

Description:
As ADC pipelines continue to grow rapidly, toxicity remains one of the biggest barriers to clinical success, patient safety, and regulatory approval. Recent safety setbacks across major ADC programs have intensified industry focus on improving toxicity prediction, translational safety assessment, and dose optimization strategies. Returning in 2026, the 4th ADC Toxicity Summit is the only dedicated industry forum exclusively focused on preventing, predicting, and mitigating ADC toxicities across preclinical and clinical development.

Bringing together toxicologists, translational scientists, pharmacologists, clinicians, and safety leaders from pharma, biotech, and academia, this summit offers a highly focused and collaborative environment to address the industry’s most urgent safety challenges. Across interactive workshops, technical case studies, panel discussions, and networking sessions, attendees will explore advanced in vitro and in vivo models, FDA New Approach Methodologies (NAMs), translational biomarkers, ILD and ocular toxicity management, and safety strategies for next-generation ADCs including dual payloads and bispecifics.